Why Is Clearside Biomedical Stock Gaining Today?
Why Is Clearside Biomedical Stock Gaining Today?
Oppenheimer initiated coverage on Clearside Biomedical Inc (NASDAQ:CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal (SCS) space.
Oppenheimer对Clearside Biomedical Inc. (纳斯达克股票代码：CLSD)进行了覆盖，这是一家专注于通过脉络膜上（SCS）空间输送治疗方法到眼底的生物制药公司。
Oppenheimer writes, "We consider Clearside a pioneer in suprachoroidal delivery via its suprachoroidal Microinjector that improves delivery of therapies for retinal diseases."
Oppenheimer写道，“我们认为，通过其脉络膜上微注射器提供的脉络膜上输送使Clearside成为脉络膜疾病治疗领域的先驱。”
Suprachoroidal drug delivery is an ocular route of drug administration.
脉络膜上药物输送是一种眼部用药途径。
The analyst writes that intravitreal injections have traditionally been the standard for delivering retinal treatments, but they can cause issues like uncontrolled dispersion.
分析师写道，玻璃体内注射传统上一直是输送视网膜治疗的标准，但其会导致无法控制的扩散等问题。
Meanwhile, SCS injections provide a more targeted and compartmentalized delivery directly into the chorioretinal tissues, ensuring high concentrations and extended effectiveness.
同时，SCS注射提供了更有针对性和隔离性的输送，直接进入脉络膜和视网膜组织，确保高浓度和长效。
Oppenheimer has initiated the coverage with an Outperform rating and a price target of $5.
Oppenheimer以跑赢市场为评级标准，给出了5美元的价格目标，并开始对Clearside Biomedical进行覆盖。
Clearside Biomedical has five ongoing collaborations and is advancing its wholly-owned CLS-AX program, a proprietary suspension formulation of axitinib for wet age-related macular degeneration (wet AMD).
Clearside Biomedical拥有5个正在进行的合作项目，并推进其完全拥有的CLS-AX项目，这是一种用于治疗湿性年龄相关性黄斑变性（湿性AMD）的专有悬浮剂制剂。
Moreover, ongoing strategic partnerships with Bausch + Lomb Corp (NYSE:BLCO) and REGENXBIO Inc (NASDAQ:RGNX) further validate the SCS Microinjector platform.
此外，与Bausch + Lomb Corp（纽交所：BLCO）和REGENXBIO Inc（纳斯达克股票代码：RGNX）的持续战略合作进一步验证了SCS微注射器平台。
With Clearside Biomedical shares trading at a discount to peers, Oppenheimer sees an opportunity for meaningful appreciation with positive results from the upcoming Phase 2b ODYSSEY in wet AMD in the third quarter of 2024.
由于Clearside Biomedical股票交易价格低于同行业公司，因此Oppenheimer认为，在2024年第三季度湿性AMD ODYSSEY的积极成果下，Clearside Biomedical有很大的升值机会。
Sales of the top-selling treatments underscore the significant market potential for effective wet AMD treatments.
畅销治疗的销售额突显了有效湿性AMD治疗的巨大市场潜力。
The global ophthalmic drugs market was valued at approximately $42.8 billion in 2022 and is projected to reach $59.1 billion by 2028.
全球眼科药物市场价值约为428亿美元，预计到2028年将达到591亿美元。
Clearside's strategic partnerships and the expansion of XIPERE into other indications (uveitic macular edema and diabetic macular edema) enhance its development capabilities and market reach, validating its technology and approach.
Clearside的战略合作伙伴以及XIPERE扩展到其他适应症（葡萄膜炎性黄斑水肿和糖尿病性黄斑水肿）增强了其开发能力和市场覆盖范围，验证了其技术和方法。
Oppenheimer writes, "With its unique broad mechanism of action inhibition, targeted delivery method, and strategic collaborations, Clearside is well positioned for success."
Oppenheimer写道，“凭借其独特的广泛作用机制、有针对性的输送方式和战略合作，Clearside已经为成功做好了充分准备。”
Price Action: CLSD shares are up 14.35% at $1.23 at last check Tuesday.
CLSD股票最近交易价格为每股1.23美元，上涨14.35%。
Photo by Amanda Dalbjörn on Unsplash
照片由Amanda Dalbérg引用Unsplash。